KR101923250B1 - 유방암의 치료 - Google Patents

유방암의 치료 Download PDF

Info

Publication number
KR101923250B1
KR101923250B1 KR1020147005617A KR20147005617A KR101923250B1 KR 101923250 B1 KR101923250 B1 KR 101923250B1 KR 1020147005617 A KR1020147005617 A KR 1020147005617A KR 20147005617 A KR20147005617 A KR 20147005617A KR 101923250 B1 KR101923250 B1 KR 101923250B1
Authority
KR
South Korea
Prior art keywords
alkyl
substituted
delete delete
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147005617A
Other languages
English (en)
Korean (ko)
Other versions
KR20140107174A (ko
Inventor
앤드류 에이. 프로터
제니퍼 리처
돈 코크런
Original Assignee
메디베이션 프로스테이트 테라퓨틱스 엘엘씨
더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101923250(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 메디베이션 프로스테이트 테라퓨틱스 엘엘씨, 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 filed Critical 메디베이션 프로스테이트 테라퓨틱스 엘엘씨
Publication of KR20140107174A publication Critical patent/KR20140107174A/ko
Application granted granted Critical
Publication of KR101923250B1 publication Critical patent/KR101923250B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147005617A 2011-07-29 2012-07-27 유방암의 치료 Active KR101923250B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
US61/513,361 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (2)

Publication Number Publication Date
KR20140107174A KR20140107174A (ko) 2014-09-04
KR101923250B1 true KR101923250B1 (ko) 2018-11-28

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147005617A Active KR101923250B1 (ko) 2011-07-29 2012-07-27 유방암의 치료

Country Status (18)

Country Link
US (4) US9517229B2 (https=)
EP (4) EP3430907A1 (https=)
JP (2) JP6158180B2 (https=)
KR (1) KR101923250B1 (https=)
CN (1) CN103997894B (https=)
BR (1) BR112014002200A2 (https=)
CA (1) CA2843417C (https=)
CY (1) CY1121038T1 (https=)
DK (1) DK2739153T3 (https=)
EA (1) EA028452B1 (https=)
ES (1) ES2696074T3 (https=)
HU (1) HUE040524T2 (https=)
MX (1) MX359664B (https=)
PH (1) PH12014500248B1 (https=)
PL (1) PL2739153T3 (https=)
PT (1) PT2739153T (https=)
SI (1) SI2739153T1 (https=)
WO (1) WO2013066440A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101923250B1 (ko) * 2011-07-29 2018-11-28 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 유방암의 치료
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
SG11201501870RA (en) 2012-09-26 2015-04-29 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG10201907684PA (en) * 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
US9937169B2 (en) * 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
WO2015069266A1 (en) * 2013-11-07 2015-05-14 Flynn Daniel L Methods for inhibiting tie2 kinase useful in the treatment of cancer
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
SG11201704425TA (en) * 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
CN107530283A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 组合脂质体药物制剂
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
LT4013412T (lt) 2019-08-12 2026-03-25 Deciphera Pharmaceuticals, Llc Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
PT4013412T (pt) 2019-08-12 2026-03-18 Deciphera Pharmaceuticals Llc Ripretinib para o tratamento de tumores estromais gastrointestinais
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
EP4188330A4 (en) * 2020-08-03 2024-09-04 Oncocyte Corporation CLASSIFICATION OF TUMORS AND PREDICTION OF RESPONSE
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004753A1 (en) 2005-05-13 2007-01-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2010099238A1 (en) 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds
WO2010118354A1 (en) 2009-04-09 2010-10-14 Medivation Prostate Therapeutics, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof
US20110003839A1 (en) 2006-03-27 2011-01-06 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
US20110130296A1 (en) 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP4644737B2 (ja) 2005-05-13 2011-03-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールヒダントイン化合物
CA2630974A1 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
KR101456722B1 (ko) * 2006-03-29 2014-10-31 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
DK2297359T3 (en) 2008-05-30 2014-02-24 Univ Utah Res Found Gene expression profiles to predict the outcome of breast cancer
WO2011022316A1 (en) * 2009-08-20 2011-02-24 The Regents Of The University Of Colorado, A Body Corporate Mirnas dysregulated in triple-negative breast cancer
AU2012229123B2 (en) 2011-03-15 2017-02-02 British Columbia Cancer Agency Branch Methods of treating breast cancer with anthracycline therapy
KR101923250B1 (ko) * 2011-07-29 2018-11-28 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 유방암의 치료
AU2012345789B2 (en) 2011-11-30 2018-02-15 British Columbia Cancer Agency Branch Methods of treating breast cancer with taxane therapy
US10175240B2 (en) 2012-08-23 2019-01-08 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
SG11201704425TA (en) 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004753A1 (en) 2005-05-13 2007-01-04 The Regents Of The University Of California Diarylhydantoin compounds
US20110003839A1 (en) 2006-03-27 2011-01-06 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US20110130296A1 (en) 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
WO2010099238A1 (en) 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds
WO2010118354A1 (en) 2009-04-09 2010-10-14 Medivation Prostate Therapeutics, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods for use thereof
WO2011044327A1 (en) 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds

Also Published As

Publication number Publication date
EP3791724A1 (en) 2021-03-17
PT2739153T (pt) 2018-11-28
PH12014500248B1 (en) 2018-08-31
WO2013066440A1 (en) 2013-05-10
EA028452B1 (ru) 2017-11-30
JP2014524934A (ja) 2014-09-25
US9517229B2 (en) 2016-12-13
HK1198867A1 (en) 2015-06-19
JP6158180B2 (ja) 2017-07-05
JP2017141269A (ja) 2017-08-17
EP3430907A1 (en) 2019-01-23
EA201400178A1 (ru) 2014-11-28
PH12014500248A1 (en) 2014-03-17
CY1121038T1 (el) 2019-12-11
US20190262315A1 (en) 2019-08-29
MX359664B (es) 2018-10-05
DK2739153T3 (en) 2018-12-03
ES2696074T3 (es) 2019-01-14
HK1201413A1 (en) 2015-09-04
EP2739153B1 (en) 2018-08-22
CN103997894B (zh) 2016-08-24
HUE040524T2 (hu) 2019-03-28
SI2739153T1 (sl) 2018-12-31
CA2843417A1 (en) 2013-05-10
BR112014002200A2 (pt) 2017-03-07
US10111861B2 (en) 2018-10-30
US20140296312A1 (en) 2014-10-02
PL2739153T3 (pl) 2019-04-30
KR20140107174A (ko) 2014-09-04
EP3610731A1 (en) 2020-02-19
US20170087132A1 (en) 2017-03-30
CN103997894A (zh) 2014-08-20
WO2013066440A9 (en) 2013-07-18
CA2843417C (en) 2018-08-21
EP2739153A4 (en) 2015-03-11
MX2014001218A (es) 2014-08-22
EP2739153A1 (en) 2014-06-11
US20210069154A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
KR101923250B1 (ko) 유방암의 치료
CN105579439B (zh) 辐射减轻性药物制剂
WO2014183673A1 (zh) 阿那格雷及其衍生物的抗肿瘤用途
US20120053559A1 (en) Treatment of Proliferative Diseases with Epothilone Derivatives and Radiation
WO2013138600A1 (en) Radioprotector compounds
CN107404876B (zh) 抗癌治疗剂
CN103619331A (zh) 抗癌治疗剂
CN109939116A (zh) Rock2抑制剂在制备药物中的用途
CN108187055B (zh) 一种具有协同增效作用的抗癌组合物
HK1201413B (en) Treatment of breast cancer
CN108299390A (zh) 抗肿瘤化合物dcz0415及其制备方法和应用
HK1198867B (en) Treatment of breast cancer
WO2024213057A1 (zh) Lsd1抑制剂与药物联用治疗癌症的用途
AU2014290012B2 (en) Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170718

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20181018

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20181122

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20181122

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210929

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20220921

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee